Clinical Trial Update: Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN) [Phase 2]

View source ↗

Summary

Phase 2 trial update for EMA401 in Painful Diabetic Neuropathy; study terminated with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Painful Diabetic Neuropathy

Drugs mentioned

• EMA401

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Painful Diabetic Neuropathy | Phase 2 | Status: TERMINATED | Results posted: 2020-06-04